Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
duocarmycin-based OHPAS payload
- Development stage
- Preclinical
- Lead developer
- IntoCell
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
The duocarmycin-based OHPAS payload is a proprietary payload-linker technology developed by IntoCell for use in the construction of antibody-drug conjugates (ADCs). It utilizes **duocarmycin**, a potent DNA minor-groove-binding alkylating agent, as the cytotoxic payload. This payload is coupled with IntoCell's proprietary **OHPAS** (Orthogonal Hydroxy Protected Azide System) linker platform, which is designed to provide high systemic stability and triggered, efficient release of the drug within target tumor cells. The OHPAS technology allows for precise control over the drug-to-antibody ratio (DAR) and aims to improve the therapeutic index of ADCs by minimizing off-target toxicity. IntoCell licenses this technology to various biopharmaceutical companies and contract development and manufacturing organizations (CDMOs), such as Piramal Pharma Solutions and Xcellon Biologics, for the development of next-generation targeted cancer therapies.
- Other names
- OHPAS-duocarmycinIntoCell duocarmycin payload-linker
02
Targets
N3-Ade (DNA adenine N3 (minor groove))
Beyond the preview
Go deeper on duocarmycin-based OHPAS payload.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on duocarmycin-based OHPAS payload.